Galecto Inc
GLTO25.260USD
+2.630+11.62%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
33.53MValor de mercado
PerdaP/L TTM
Mais detalhes de Galecto Inc Empresa
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Informações de Galecto Inc
Código da empresaGLTO
Nome da EmpresaGalecto Inc
Data de listagemOct 29, 2020
CEOSchambye (Hans T)
Número de funcionários5
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 29
Endereço75 State Street
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02109
Telefone14570705210
Sitehttps://galecto.com/
Código da empresaGLTO
Data de listagemOct 29, 2020
CEOSchambye (Hans T)
Executivos da empresa Galecto Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
--
-192.00%
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
+425.00%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
+239.00%
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 1 de fev
Atualizado em: dom, 1 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Outro
31.04%
Investidores
Investidores
Proporção
Ikarian Capital LLC
17.91%
Hewes (Lemuel Becker)
16.59%
Fidelity Management & Research Company LLC
14.98%
Sattarzadeh (Sherwin)
11.93%
Paramora Holding LLC
7.55%
Outro
31.04%
Tipos de investidores
Investidores
Proporção
Individual Investor
32.16%
Hedge Fund
28.17%
Investment Advisor
17.71%
Corporation
15.10%
Venture Capital
1.85%
Research Firm
1.24%
Investment Advisor/Hedge Fund
0.67%
Outro
3.10%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
45
791.78K
49.64%
+565.88K
2025Q3
44
164.38K
12.40%
-149.96K
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Ikarian Capital LLC
285.71K
17.91%
+285.71K
--
Nov 30, 2025
Fidelity Management & Research Company LLC
238.88K
14.98%
+238.88K
--
Nov 28, 2025
Point72 Asset Management, L.P.
100.00K
6.27%
+100.00K
--
Nov 12, 2025
Goldfischer (Carl S)
41.96K
2.63%
-1.00
-0.00%
Dec 01, 2025
Danmarks Eksport- og Investeringsfond
29.52K
1.85%
-29.52K
-50.00%
Sep 30, 2024
Connective Capital Management, LLC
26.96K
1.69%
+26.96K
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
